Bath Savings Trust Co lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 116.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,448 shares of the medical research company’s stock after acquiring an additional 7,240 shares during the period. Bath Savings Trust Co’s holdings in Edwards Lifesciences Corporation were worth $1,470,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. Ardsley Advisory Partners raised its stake in shares of Edwards Lifesciences Corporation by 60.0% in the 2nd quarter. Ardsley Advisory Partners now owns 4,000 shares of the medical research company’s stock valued at $473,000 after acquiring an additional 1,500 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Edwards Lifesciences Corporation in the 2nd quarter valued at approximately $140,000. Lord Abbett & CO. LLC raised its stake in shares of Edwards Lifesciences Corporation by 58.4% in the 2nd quarter. Lord Abbett & CO. LLC now owns 83,718 shares of the medical research company’s stock valued at $9,899,000 after acquiring an additional 30,875 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Edwards Lifesciences Corporation by 24.0% in the 2nd quarter. Toronto Dominion Bank now owns 71,106 shares of the medical research company’s stock valued at $8,406,000 after acquiring an additional 13,747 shares in the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of Edwards Lifesciences Corporation by 0.9% in the 2nd quarter. Advisory Services Network LLC now owns 12,565 shares of the medical research company’s stock valued at $1,486,000 after acquiring an additional 112 shares in the last quarter. 81.90% of the stock is currently owned by institutional investors and hedge funds.
Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 1.31% during mid-day trading on Tuesday, reaching $109.94. The company had a trading volume of 341,841 shares. The firm’s 50 day moving average is $111.37 and its 200-day moving average is $111.56. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The stock has a market capitalization of $23.21 billion, a P/E ratio of 33.35 and a beta of 0.62.
Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The business had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.76 earnings per share. On average, analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.
WARNING: “Edwards Lifesciences Corporation (EW) Position Lifted by Bath Savings Trust Co” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/17/edwards-lifesciences-corporation-ew-position-lifted-by-bath-savings-trust-co.html.
A number of research analysts recently weighed in on the company. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Jefferies Group LLC reissued a “buy” rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. SunTrust Banks, Inc. raised their price objective on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $120.75.
In related news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $108.54, for a total value of $2,057,918.40. The disclosure for this sale can be found here. Insiders have sold 201,161 shares of company stock worth $22,826,072 in the last three months. 2.13% of the stock is currently owned by company insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.